Cardiovascular Risk of First-Line Osimertinib vs EGFR-TKIs in EGFR-Mutant NSCLC: A TriNetX USA Network Analysis

作者：Wen Cheng, Chih‐Yen Tu, Te‐Chun Hsia, Jing Yang Huang, Ying‐Hsiang Chou, James Cheng‐Chung Wei · 发表于：SSRN Electronic Journal · 年份：2025 · DOI：10.2139/ssrn.5199063 · 研究领域：Lung Cancer Treatments and Mutations、Chronic Myeloid Leukemia Treatments、Synthesis and biological activity